3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Stomach Neoplasms
15
Carcinoma, Non-Small-Cell Lung
13
Neoplasms
9
Colorectal Neoplasms
7
Carcinoma, Hepatocellular
7
Colonic Neoplasms
5
Breast Neoplasms
5
Adenocarcinoma
5
Neoplasm Metastasis
4
Lung Neoplasms
4
Carcinoma, Renal Cell
4
Urethral Neoplasms
3
Rectal Neoplasms
3
Liver Neoplasms
3
Esophageal Neoplasms
3
Urinary Bladder Neoplasms
2
Ureteral Neoplasms
2
Pancreatic Neoplasms
2
Melanoma
2
Malignant Solid Tumor
2
Carcinoma, Transitional Cell
2
Thymoma
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
Ramucirumab
1
Fluorouracil
1
Cisplatin
1
Capecitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metastatic Gastric Adenocarcinoma
×
Ramucirumab
×
Clear all
NCT02314117
2021-08-26
RAINFALL
Eli Lilly and Company
Phase 3
Completed
645 enrolled
22 charts